CD31 density is a novel risk factor for patients with B-cell chronic lymphocytic leukaemia

  • Authors:
    • Tryfonia Mainou-Fowler
    • Alistair Porteous
    • Annette Nicolle
    • Stephen John Proctor
    • John James Anderson
    • Geoffrey Summerfield
  • View Affiliations

  • Published online on: July 1, 2008     https://doi.org/10.3892/ijo.33.1.169
  • Pages: 169-174
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

CD31 is the physiological ligand for CD38. CD38 expression in a high percentage of malignant cells is a risk factor for patients with B-cell chronic lymphocytic leukaemia (B-CLL). A previous investigation demonstrated that quantification of CD38 improves upon the prognostic value of the percentage expression. A recent study states that the percentage of CD31 expression is not predictive in B-CLL. We reassessed the predictive power of CD31 in a cohort of 120 patients with B-CLL. Peripheral blood cells were stained with PCP-labelled anti (α)-CD19, FITC-α-CD5 and PE-α-CD31 antibodies. CD31 expression was quantified using beads of specific antibody binding capacity and the density was correlated with clinical outcome. End points were disease-specific survival and time to treatment (TTT). We report that CD31 density was significantly lower in the group of patients with Binet stage B and C of disease progression (P=0.0003). There was an inverse, significant correlation between CD31 and CD38 densities (R=−0.281, P=0.002). All CLL-related deaths occurred in patients with low CD31 density. Low CD31 predicted for poor disease outcome (survival, P=0.0087; TTT, P=0.0064) and identified Binet stage A patients (survival, P=0.0350; TTT, P=0.0716) and those with low CD38 (survival: all patients, P<0.0001; stage A, P=0.003) who followed a more aggressive clinical course. Disease-specific survival of patients with low CD31 and high CD38 densities was significantly shorter than all other groups. In addition, low CD31 density was a poor risk factor irrespective of patient age (survival: all patients, P=0.045; stage A, P=0.021) and identified patients with Binet stage B/C as the highest risk group (P<0.0001). In conclusion, low CD31 density is an adverse prognostic indicator in B-CLL. Also, low CD31 density enhances the prognostic power of CD38 density. The interaction between CD31 and CD38 and its clinical significance in B-CLL requires further investigation.

Related Articles

Journal Cover

July 2008
Volume 33 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Mainou-Fowler T, Porteous A, Nicolle A, Proctor SJ, Anderson JJ and Summerfield G: CD31 density is a novel risk factor for patients with B-cell chronic lymphocytic leukaemia. Int J Oncol 33: 169-174, 2008
APA
Mainou-Fowler, T., Porteous, A., Nicolle, A., Proctor, S.J., Anderson, J.J., & Summerfield, G. (2008). CD31 density is a novel risk factor for patients with B-cell chronic lymphocytic leukaemia. International Journal of Oncology, 33, 169-174. https://doi.org/10.3892/ijo.33.1.169
MLA
Mainou-Fowler, T., Porteous, A., Nicolle, A., Proctor, S. J., Anderson, J. J., Summerfield, G."CD31 density is a novel risk factor for patients with B-cell chronic lymphocytic leukaemia". International Journal of Oncology 33.1 (2008): 169-174.
Chicago
Mainou-Fowler, T., Porteous, A., Nicolle, A., Proctor, S. J., Anderson, J. J., Summerfield, G."CD31 density is a novel risk factor for patients with B-cell chronic lymphocytic leukaemia". International Journal of Oncology 33, no. 1 (2008): 169-174. https://doi.org/10.3892/ijo.33.1.169